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Totally implantable venous access port systems and risk factors for complications: A one-year prospective study in a cancer centre 
Introduction
First introduced in the early 1980s, totally implantable venous access port systems (TIVAPS) are now routinely used in oncology, facilitating long-term chemotherapy and other precedures. [1, 2] Although TIVAPS are generally associated with a lower long-term risk of infection compared to Hickman-type central venous catheters, [3, 4] complications during their placement and long-term use are still a matter of concern. These complications, including infection, catheter fracture, thrombosis and extravasation [5, 6, 7] , may necessitate device replacement, resulting in additional patient stress and treatment delays. Cancer patients have an intrinsically high risk of venous thrombosis, related to both the disease process itself and certain cancer treatments, [8] this risk being further increased by placement of a catheter or TIVAPS. [1] Several studies in cancer patients have investigated potential risk factors for TIVAPS-related complications, including the vein accessed [5, 9, 10] and patient age and gender [11, 12] analysis of paediatric patients, showed a higher risk of infection after TIVAPS implantation in younger patients. [12] In view of the importance of minimising complications associated with TIVAPS and the few data available on potential risk factors, we initiated a large-scale prospective, observational study to explore this issue in the context of routine clinical practice in our cancer treatment centre.
Patients and methods

Study design
This was a prospective, observational, descriptive study of the insertion and use of TIVAPS in a specialised cancer treatment center. The primary objective was to determine the complications associated with TIVAPS during the year following their insertion and to analyse the risk factors for these. The complications assessed were specified prior to the study in the protocol and case report form (CRF). The secondary objective was to evaluate patient satisfaction with TIVAPS placement (particularly in terms of pain, discomfort and aesthetic outcome) and quality of life.
Inclusion and exclusion criteria
Adult and paediatric patients with documented cancer treated in the Oscar Lambret Regional Anticancer Centre (Lille, France) and requiring long-term venous access were eligible to enter the study provided they met none of the specified exclusion criteria. These comprised medical contraindication to surgical intervention M A N U S C R I P T 
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Statistical analysis
Qualitative variables were expressed as the median and range, and the mean and standard deviation. 
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Results
Patient population
A total of 815 consecutive cancer patients (552 female) undergoing TIVAPS placement and meeting the specified selection criteria were enrolled between May 
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Complications
No deaths occurred during the study. necessitated premature device removal in 55 patients after a mean (± SD) of 4.5 ± 3.5 months (median: 3.7 months; range: 0.2-12.0). In 64 patients, the TIVAPS was removed before the end of the two-year follow-up period owing to completion of chemotherapy, the median and mean (± SD) intervals between TIVAPS insertion and removal being respectively 7.5 months (3.7 -12.0) and 7.7 ± 2.6 months. In contrast, the interval between TIVAPS implantation and first use had a statistically significant impact on the overall complication rate, and the frequency of skin disorders and infections. The median intervals between device implantation and first use in patients with and without complications were respectively 6 days (range 0-53) and 8 days (range 0-135). The mean (± SD) intervals between device placement and first use were respectively 13.1 ± 15.2 days and 9.1 ± 9.7 days (p=0.005). The overall incidence of complications progressively diminished with increasing interval M A N U S C R I P T respectively, when the TIVAPS was first used 0-3 days, 4-7 days and more than 7 days after its insertion (p<0.0001).
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Multivariate logistic regression analysis showed that the complication rate increased with difficulty in TIVAPS insertion when the interval between insertion and first use was ≤ 7 days, but not when it was 8 days or more. The rate of premature device removal owing to complications was 30/353 when the interval between insertion and first use was less than 8 days and 20/405 when it was 8 days or more.
This difference was at the limit of statistical significance (p=0.05, Chi 2 test) and no longer significant when the Yates correction was applied.
Quality of life and patient satisfaction with TIVAPS placement and use
Although all adult patients were invited to complete the EORTC QLQ-C30 quality of life questionnaire, just before TIVAPS placement and the first and fourth cycles of chemotherapy, and the questionnaire on satisfaction just before the fourth chemotherapy cycle, only a minority did so. Depending on the item considered, between 291 and 319 patients were evaluable for the comparison of QLQ-C30 quality of life scores between TIVAPS insertion and first use.
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No decrease in global health status or quality of life was evident, although small but statistically significant changes were seen in certain individual functional scales (decrease in physical, role, emotional and social functioning) and one of the symptom scales (increase in pain). Comparison of the scores between TIVAPS insertion and the start of the fourth chemotherapy cycle (150-160 patients evaluable depending on the item) gave similar results. Global health status and quality of life remained unchanged, but there was a statistically significant decrease in scores for physical (p=0.001) and emotional (p=0.0002) functioning.
Only 171 patients responded to the questionnaire on satisfaction just before the fourth course of chemotherapy. Concerning TIVAPS-related pain, 100/167 patients stated that they felt no pain, 47 declaring slight pain. Similarly, 115/169 patients maintained that the device was not an obstacle to performing any activities, 43 considering that it only slightly hampered their activities. Most patients (118/166) considered that the scars were at least satisfactory from an aesthetic standpoint and that the scars, the port and the attached catheter did not impair their ability to dress themselves and were not overly visible. Patients in whom TIVAPS insertion had involved cephalic vein access (one scar) rated the aesthetic appearance of their scars significantly more highly than those in whom the external jugular vein had been accessed (p=0.01; chi 2 test), the latter procedure resulting in two scars. They were also significantly less bothered by visibility of the catheter (p=0.001; chi 2 test).
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Discussion
Incidence of complications
The overall incidence of complications in our study (16.1%) was similar to those reported after TIVAPS implantation in cancer patients by Wolosker et al. [13] [10] in the case of internal jugular vein access (7.6%), Hartkamp et al. [7] reporting a higher rate (25.2%). As in other studies, [7, 9, 11, 13, 14] the main complication observed in our study was infection, occurring in 5.3% of patients and accounting for half the total number of premature device removals.
Risk factors for complications
Among the wide range of variables investigated, only the time elapsing between implantation of the TIVAPS and its first use had a statistically significant effect on the overall rate of complications. The complication rate was significantly higher when the interval between implantation and first use was at least 8 days and a strong trend towards a higher incidence of premature removal of the TIVAPS due to complications was also observed. To the best of our knowledge, this relationship has not been reported in previous studies and warrants further investigation. One possible explanation for these findings might be that healing of the incision made to inset the device is less likely to be complete and fully capable of withstanding the strains involved in TIVAPS use when this occurs less than 8 days after device placement. In cancer patients, the administration of aggressive cytotoxic drugs might then further increase the risk of complications by hindering the completion of wound healing.
In our study, the vein catheterised was predominantly either the external jugular vein or the cephalic vein, these veins similarly being the principal site of TIVAPS insertion in the studies reported by Wolosker et al. [13] and Hsieh et al. [11] , respectively. The overall complication rate did not differ significantly according to the vein accessed. However, both inflammation and port expulsion were significantly less frequent when the the cephalic vein was catheterised. Patient satisfaction was also greater with cephalic vein catheterisation, with regard to both the esthetic appearance of the incision scar and visibility of the catheter. The results of previous studies vary, showing either an effect [10] or no effect [5, 6, 11] of the vein accessed on complication rates, but the veins compared differ from one study to another.
Quality of life
The observational and routine practice nature of our study probably contributed to the rather high numbers of missing data for certain variables, particularly those 
